Detalhe da pesquisa
1.
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
BMC Cancer
; 19(1): 366, 2019 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30999949
2.
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Future Oncol
; 15(16): 1811-1822, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30969136
3.
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
BMC Cancer
; 17(1): 332, 2017 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28511673
4.
Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
J Am Acad Dermatol
; 77(4): 713-718, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28780365
5.
A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
J Am Acad Dermatol
; 73(1): 99-105.e1, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25913533
6.
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
J Am Acad Dermatol
; 72(6): 1021-6.e8, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25981002
7.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
N Engl J Med
; 364(26): 2507-16, 2011 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-21639808
8.
Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Cancer Gene Ther
; 12(6): 540-51, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15678150
9.
The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010.
Eur J Dermatol
; 25(5): 463-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26105129
10.
Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease.
Eur J Cancer
; 50(4): 774-83, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24412051
11.
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production.
Blood
; 109(12): 5399-406, 2007 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17344465
12.
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
J Clin Oncol
; 25(27): 4270-7, 2007 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17878479
13.
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant
; 12(11): 1150-60, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17085308
14.
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Biol Blood Marrow Transplant
; 9(3): 162-9, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12652466
15.
Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease.
Clin Gastroenterol Hepatol
; 2(3): 237-45, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15017608